-
NRG-GI011 A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)
NRG-GI011, A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)Phase
Interventional
-
A Phase 3 Double-blind Placebo-controlled Randomized Study to Assess the Efficacy and Safety of ASP3082 in Combination with mFOLFIRINOX or NALIRIFOX as First-line Treatment in Participants with KRAS G12D-mutated Metastatic Pancreatic Adenocarcinoma
This is a Phase 3 study testing a new drug called ASP3082 to see if it works well and is safe when combined with two ...
Phase
Interventional
-
A Randomized Phase 2/3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring
CA240-0030 A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants ...Phase
Interventional
-
A Phase 3 Multicenter Open-label Randomized 2 Arm Study of Adjuvant Daraxonrasib versus Observation Following Curative Intent Therapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)
This is a Phase 3 study for patients with Pancreatic Ductal Adenocarcinoma (PDAC) whose cancer has been removed by surgery. The study is randomized and ...
Phase
Interventional
-
A Phase 3 Randomized Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus the Standard Gemcitabine and nab-Paclitaxel Regimen for the Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma Cancer (MAPKeeper 301)
This is a Phase 3 study testing how safe and effective a new drug combination is for people with metastatic pancreatic cancer (PDAC) who have ...
Phase
Interventional
-
A Randomized Double-Blind Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated KRAS G12D Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
This is a Phase 3 study for people with metastatic pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer. To join the study ...
Phase
Interventional
-
A Phase 1/2 Multicenter Open-Label Study to Evaluate the Safety Tolerability and Preliminary Antitumor Activity of TNG462 in Combination with Other Agents in Patients with Pancreatic or Non-Small Cell Lung Cancer with MTAP Loss and RAS Mutation
This Phase 1/2 study will determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236 or RMC-9805 ...Phase
Interventional
-
EXtending outcomes for PAncreas cancer patients with Nominal oligometastatic Disease (EXPAND): A randomized phase III trial
This is a study to determine whether, in patients with oligometastatic pancreatic ductal adenocarcinoma, metastasis-directed therapy to all sites of disease confers a benefit in ...Phase
Interventional
-
Phase 1/1b Multicenter Open-Label Study of RMC-5127 in Patients with Advanced KRAS G12V-Mutant Solid Tumors
This is a Phase 1/1b study testing RMC-5127 (investigational cancer drug) in adults with advanced solid tumors that have a KRAS G12V mutation, a ...
Phase
Interventional
-
A Phase 1a/1b Open-Label Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of BBO-11818 in Subjects with Advanced KRAS Mutant Cancers
This is a Phase 1 study testing whether the study medicine BBO-11818 (a pan-KRAS inhibitor) is safe and effective in patients with locally advanced solid ...
Phase
Interventional
